REINACH and BASEL, Switzerland, September 19 /PRNewswire-FirstCall/ -- Arpida Ltd (SWX: ARPN) presented a large body of preclinical and clinical data on its investigational drug iclaprim at the 47th annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Chicago. ICAAC is a major scientific conference where thousands of scientists and clinicians from all over the world gather to discuss the latest developments in the field of infectious diseases.
Iclaprim is a novel late stage investigational antibiotic which exhibits potent activity against Gram-positive bacteria including those resistant to current therapies, e.g., MRSA, VISA, VRSA etc. In three separate efficacy trials, iclaprim has been compared against either linezolid or vancomycin and has consistently shown high clinical cure rates. Moreover, clinical experience to date shows that iclaprim is well-tolerated in patients and volunteers. New data presented at ICAAC included large surveillance studies on recent clinical isolates, quality control and CLSI parameters for susceptibility testing, Phase I pharmacokinetic studies and results from the first pivotal Phase III clinical trial (ASSIST-1).
L-1142: ASSIST-1 data on microbiological efficacy in complicated Skin and Skin Structure Infections (cSSSI). Iclaprim showed high microbiological eradication rates against major cSSSI pathogens, comparable with linezolid (MRSA eradication rates were 84.7% vs. 85.3%, respectively). Additional clinical data on safety and efficacy will be presented in October at the upcoming IDSA meeting in San Diego.
E-902, E-904, E-910, E-911: Four posters presented data on large susceptibility studies against recent clinical isolates: iclaprim was the most active compound tested in a study against community-acquired and nosocomial Staphylococcus aureus (poster E-904) and it showed good activity against streptococci and enterococci.
E-906: Iclaprim exhibited rapid bactericidal activi
|SOURCE Arpida Ltd|
Copyright©2007 PR Newswire.
All rights reserved